Fortress Biotech Valuation Multiples

Fortress Biotech Overview

About Fortress Biotech

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

Founded

2006

HQ

Employees

101

Website

fortressbiotech.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $72M

EBITDA: ($48M)

EV

$72M

Valuation Multiples

Multiples.vc

Start free trial

Fortress Biotech Financials

Fortress Biotech reported last 12-month revenue of $72M and negative EBITDA of ($48M).

In the same LTM period, Fortress Biotech generated $46M in gross profit, ($48M) in EBITDA losses, and had net loss of ($1M).

Fortress Biotech P&L

In the most recent fiscal year, Fortress Biotech reported revenue of $63M and EBITDA of ($20M).

Fortress Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

Fortress Biotech Stock Performance

Fortress Biotech has current market cap of $77M, and enterprise value of $72M.

Fortress Biotech's stock price is $2.41.

Fortress Biotech Valuation Multiples

Fortress Biotech trades at 1.0x EV/Revenue multiple, and (1.5x) EV/EBITDA.

Fortress Biotech Financial Valuation Multiples

As of April 11, 2026, Fortress Biotech has market cap of $77M and EV of $72M.

Equity research analysts estimate Fortress Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Fortress Biotech has a P/E ratio of (56.4x).

Fortress Biotech Margins & Growth Rates

Fortress Biotech's revenue in the last 12 month grew by 48%.

Fortress Biotech's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.1M for the same period.

Fortress Biotech's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Fortress Biotech's rule of X is 96% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Fortress Biotech Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Fortress Biotech M&A Activity

Fortress Biotech acquired XXX companies to date.

Last acquisition by Fortress Biotech was on XXXXXXXX, XXXXX. Fortress Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Fortress Biotech Investment Activity

Fortress Biotech invested in XXX companies to date.

Fortress Biotech made its latest investment on XXXXXXXX, XXXXX. Fortress Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).